Avandamet OK to use first
Prescribing physicians will now be able to initiate treatment for Type 2 diabetes with GlaxoSmithKline's Avandamet, a combination product containing both rosiglitazone maleate and metformin HCl, following a recent approval by the FDA. Previously, the drug was approved only as a second-line therapy in patients whose diabetes was uncontrolled on metformin alone.
Avandamet OK to use first
Prescribing physicians will now be able to initiate treatment for Type 2 diabetes with GlaxoSmithKline's Avandamet, a combination product containing both rosiglitazone maleate and metformin HCl, following a recent approval by the FDA. Previously, the drug was approved only as a second-line therapy in patients whose diabetes was uncontrolled on metformin alone. Avandamet was first approved in 2002 and is available in four tablet strengths of rosiglitazone/metformin: 2 mg/500 mg, 4 mg/500 mg, 2 mg/1000 mg, and 4 mg/1000 mg. GSK also announced that there is no shortage of Avandamet now.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
Q&A: Retail, Independent Pharmacies Continue to Call for Improved Reimbursement Practices
June 30th 2025Rick Gates, chief pharmacy officer at Walgreens and chairman of the National Association of Chain Drug Stores, discussed the current status of retail pharmacies and the way they are reimbursed.
